|
T35530 |
IHMT-PI3Kδ-372
|
IHMT-PI3Kδ-372 |
PI3K
|
|
IHMT-PI3Kδ-372 is a selective inhibitor of PI3Kδ with an IC50 of 14 nM and can be used in studies about chronic obstructive pulmonary disease. |
|
T12462 |
PI3Kδ-IN-1
|
|
PI3K
|
|
PI3Kδ-IN-1 is an efficacious PI3Kδ inhibitor (IC50 of 1.7 nM). |
|
T6330 |
Linperlisib
|
PI3Kδ-IN-2 |
PI3K
|
|
Linperlisib (PI3Kδ-IN-2) is a potent and selective inhibitor of PI3Kδ |
|
T5831 |
Selective PI3Kδ Inhibitor 1
|
|
PI3K
|
|
Selective PI3Kδ Inhibitor 1 is a PI3Kδ Inhibitor( IC50 = 0.9 nM). |
|
T26252 |
PI3Kδ-IN-3
|
TC KHNS 11 |
PI3K
|
|
PI3Kδ-IN-3 (TC KHNS 11) is a PI3Kδ inhibitor with an IC50 value of 9 nM.PI3Kδ-IN-3 has a favorable pharmacokinetic profile and inhibits B cell function. |
|
T60196 |
IHMT-PI3Kδ-372 S-isomer
|
|
PI3K
|
|
IHMT-PI3Kδ-372 S-isomer is a potent and selective PI3Kδ inhibitor with an IC50 of 14 nM. IHMT-PI3Kδ-372 S-isomer shows high selectivity over other class I PI3Ks (56∼83 fold) and other protein kinases. IHMT-PI3Kδ-372 can ... |
|
T39542 |
PI3Kδ-IN-8
|
PI3Kδ-IN-8 |
|
|
PI3Kδ-IN-8 is a powerful and specific oral inhibitor of PI3Kδ, exhibiting an IC50 of 3.3 nM. It demonstrates preferential inhibition of PI3Kδ when compared to PI3Kα, PI3Kβ, and PI3Kγ, with IC50 values of 377.2 nM, 241.6 ... |
|
T39592 |
PI3Kδ-IN-9
|
PI3Kδ-IN-9 |
|
|
PI3Kδ-IN-9 is a selective PI3Kδ inhibitor with an IC 50 value of 3.8 nM. |
|
T77667 |
PI3Kδ-IN-16
|
|
Apoptosis
,
PI3K
|
|
PI3Kδ-IN-16 is a selective and potent PI3Kδ inhibitor with anticancer and antiproliferative activity, induces cell cycle arrest and apoptosis. |
|
T12463 |
PI3kδ inhibitor 1
|
|
PI3K
|
|
PI3kδ inhibitor 1 is a selective inhibitor of PI3Kδ (IC50 of 3.8 nM). |
|
T81467 |
PI3Kδ-IN-18
|
|
PI3K
|
|
Se15, a selective PI3Kδ inhibitor, exhibits potency with an IC50 value of less than 0.1nM and is utilized in autoimmune research [1]. |
|
T78691 |
PI3Kδ-IN-12
|
|
PI3K
|
|
PI3Kδ-IN-12 (compound 13), a PI3Kδ inhibitor with a pIC50 of 5.8, exhibits differential binding affinities with pKi values of 8.0 for PI3Kδ, 6.5 for PI3Kγ, 6.4 for PI3Kβ, and 6.7 for PI3Kα. This compound is utilized in r... |
|
T62013 |
PI3Kδ-IN-10
|
|
|
|
PI3Kδ-IN-10 is a highly potent and orally active PI3Kδ inhibitor (IC50= 2 nM). In hepatocellular carcinoma models, PI3Kδ-IN-10 robustly suppresses the downstream AKT pathway to induce subsequent apoptosis. |
|
T79658 |
PI3Kδ-IN-14
|
|
PI3K
|
|
PI3Kδ-IN-14 (Compound (S)-29), a selective PI3Kδ inhibitor with an IC50 of 0.8 nM and a Kd of 84.8 nM, targets the ATP-binding site within the kinase domain of PI3Kδ. This compound exhibits anti-inflammatory properties b... |
|
T81468 |
PI3Kδ-IN-17
|
|
PI3K
|
|
PI3Kδ-IN-17 (Compound S5) is a potent PI3K δ inhibitor, exhibiting an IC50 value of 2.82 nM and demonstrates significant efficacy in suppressing the proliferation of SU-DHL-6 cells with an IC50 of 0.035 μM [1]. |
|
T62408 |
PI3Kδ-IN-11
|
|
|
|
PI3Kδ-IN-11 is a potent and selective PI3Kδ inhibitor (IC50: 27.5 nM) that dose-dependently blocks PI3K/Akt pathway activity. PI3Kδ-IN-11 can be used in B- or T-cell-associated malignancy studies. |
|
T78568 |
PI3Kδ-IN-15
|
|
PI3K
|
|
PI3Kδ-IN-15 (compound 6b) is a potent and selective inhibitor of PI3Kδ, exhibiting an IC50 of 0.5 nM for p110δ and demonstrating over 30-fold selectivity compared to PI3K isoforms γ, β, and α [1]. |
|
T79627 |
PI3Kδ-IN-13
|
|
PI3K
|
|
PI3Kδ-IN-13 (compound 89), with an IC50 value of 2.6 nM, is an inhibitor of PI3Kδ, applicable for researching diseases involving cell proliferation, including cancer, infection, inflammation, and autoimmune disorders [1]... |
|
T63497 |
PI3Kδ/γ-IN-1
|
|
|
|
PI3Kδ/γ-IN-1 is a selective and effective inhibitor of PI3Kδ/γ that can be used in the treatment of hematologic malignancies. |
|
T63221 |
PI3Kδ/γ-IN-2
|
|
|
|
PI3Kδ/γ-IN-2 is a potent, orally bioavailable dual inhibitor of PI3Kδ (IC50: 1 nM) and PI3Kγ (IC50: 4.3 nM) with potential for use in anti-B-cell malignancy studies. |
|
T63078 |
PI3Kδ/γ-IN-3
|
|
|
|
PI3Kδ/γ-IN-3 (Compound 58) is an orally active dual inhibitor of PI3Kδ (IC50: 1 nM) and PI3Kγ (IC50: 16 nM). PI3Kδ/γ-IN-3 can induce apoptosis of tumor cells, which can be used in the study of B-cell malignant tumors. |
|
T6704 |
TG 100713
|
TG100713 |
PI3K
|
|
TG 100713 is a pan-PI3K inhibitor against PI3Kγ, PI3Kδ, PI3Kα and PI3Kβ with IC50 of 50 nM, 24 nM, 165 nM and 215 nM, respectively. |
|
T12367 |
Parsaclisib
|
INCB050465 |
PI3K
|
|
Parsaclisib (INCB050465) is a potent and selective inhibitor of PI3Kδ(IC50 of 1 nM at 1 mM ATP) |
|
T14214 |
AMG 511
|
|
PI3K
|
|
AMG 511 is a potent and orally available pan inhibitor of class I PI3Ks(Kis of 4 nM, 6 nM, 2 nM and 1 nM for PI3Kα, β, δ and γ, respectively). It exhibits anti-tumor activity in mouse glioblastoma xenograft model[1]. AMG... |
|
T22339 |
GNE-490
|
|
Others
,
PI3K
|
|
GNE-490 is an effective inhibitor of pan-PI3K with IC50s of 3.5 nM, 25 nM, 5.2 nM, 15 nM for PI3Kα, PI3Kβ, PI3Kδ and PI3Kγ, respectively. GNE-490 has >200 fold selectivity for mTOR (IC50 = 750 nM). |
|
T12461 |
PI3Kdelta inhibitor 1
|
|
PI3K
|
|
PI3Kdelta inhibitor 1 is a potent, selective and orally available inhibitor of PI3Kδ with an IC50 of 1.3 nM. |
|
T6850 |
GSK2292767
|
|
PI3K
|
|
GSK2292767 is a potent and selective PI3Kδ inhibitor. |
|
T28297 |
Parsaclisib hydrochloride
|
Parsaclisib HCl,INCB-50465,INCB 050465,INCB-050465,INCB050465 HCl,INCB 50465,INCB50465 HCl |
PI3K
|
|
Parsaclisib hydrochloride (INCB050465 HCl) is a selectve PI3Kδ inhibitor with antitumor activity. Parsaclisib demonstrates potent activity with IC50 values ranging from 0.2 to 2 nM. |
|
T6757 |
AMG319
|
|
PI3K
|
|
AMG319 is a potent and selective PI3Kδ inhibitor with IC50 of 18 nM, >47-fold selectivity over other PI3Ks. Phase 2. |
|
T2660 |
IC-87114
|
IC 87114 |
PI3K
|
|
IC-87114 is a specific PI3Kδ inhibitor(IC50=0.5 μM). |
|
T4976 |
Umbralisib
|
TGR-1202,RP5264,TGR 1202,TGR1202 |
PI3K
|
|
Umbralisib (TGR 1202) is a PI3Kδ inhibitor. |
|
T12115 |
MSC2360844
|
|
PI3K
|
|
|
|
TQ0044 |
Seletalisib
|
UCB5857 |
PI3K
|
|
Seletalisib (UCB5857) (UCB5857) is a potent and specific PI3Kδ inhibitor (IC50: 12 nM). |
|
T15420 |
GS-9901
|
|
PI3K
|
|
GS-9901 is a selective, orally active and potent PI3Kδ inhibitor (IC50: 1 nM) for the study of non-Hodgkin's lymphoma and chronic lymphocytic leukemia. |
|
T13119 |
Tenalisib
|
RP6530 |
PI3K
|
|
Tenalisib (RP6530) (RP6530) is a potent and selective inhibitor of PI3Kδ and PI3Kγ(IC50 values of 25 and 33 nM, respectively.) |
|
T5166 |
Leniolisib
|
CDZ173 |
DNA-PK
,
PI3K
|
|
Leniolisib (CDZ173) (CDZ173) is a potent and selective PI3Kδ inhibitor (IC50: 11 nM). |
|
T3348 |
PIK-293
|
PIK293 |
PI3K
|
|
PIK-293 is a PI3K inhibitor, for PI3Kδ( IC50=0.24 μM), and less potent for PI3Kα/β/ γ. |
|
T15431 |
Nemiralisib
|
GSK2269557 (free base),GSK2269557 |
PI3K
|
|
Nemiralisib（GSK-2269557 free base） is an orally available, potent and specific PI3Kδ inhibitor with a pKi of 9.9.Nemiralisib is used for the treatment of respiratory diseases including chronic obstructive pulmonary disea... |
|
T6557 |
KU-0060648
|
KU0060648 |
DNA-PK
,
PI3K
,
mTOR
|
|
KU-0060648 is a dual inhibitor of DNA-PK and PI3Kα, PI3Kβ, PI3Kδ with IC50 of 8.6 nM and 4 nM, 0.5 nM, 0.1 nM respectively, less inhibition of PI3Kγ with IC50 of 0.59 μM. |
|
T12310 |
ON 146040
|
ZINC211117138 |
PI3K
,
Bcr-Abl
|
|
|
|
T7166 |
GNE-493
|
|
PI3K
,
mTOR
|
|
GNE-493 is potent, selective, and orally available PI3K and mTOR inhibitor with potential anticancer activity.IC50s of 3.4 nM, 12 nM, 16 nM, 16 nM and 32 nM for PI3Kα, PI3Kβ, PI3Kδ, PI3Kγ and mTOR,respectively. |
|
T2682 |
Acalisib
|
GS-9820,CAL-120 |
PI3K
|
|
Acalisib (CAL-120) (GS-9820) is a potent and selective inhibitor of PI3Kδ. |
|
T12459 |
PI3K/mTOR Inhibitor-2
|
|
PI3K
,
mTOR
|
|
|
|
TQ0229 |
ETP-46321
|
|
PI3K
|
|
ETP-46321 is an effective and orally bioavailable PI3Kα/PI3Kδ inhibitor (Ki: 2.3/14.2 nM). |
|
T21938 |
AS-041164
|
|
PI3K
|
|
AS-041164 is a selective and orally active PI3Kγ isoform inhibitor(IC50 of 70 nM), and shows less activity against PI3Kα, PI3Kβ, and PI3Kδ (IC50s of 240 nM, 1.45 μM, and 1.70 μM, respectively). It has anti-inflammatory e... |
|
T39573 |
GSK251
|
|
PI3K
|
|
GSK251 is a novel, orally bioavailable inhibitor of PI3Kδ, exhibiting high potency and selectivity, with a unique binding mode. |
|
T9788 |
SN32976
|
|
PI3K
|
|
SN32976 is a pan PI3K inhibitor. SN32976 potently inhibited PI3K isoforms and mTOR, displaying preferential activity for PI3Kα and sparing of PI3Kδ. |
|
T3656 |
PKI-402
|
|
PI3K
,
mTOR
|
|
PKI-402 is a potent PI3K and mTOR inhibitor. PKI-402 inhibits PI3Kα, mTOR, PI3Kβ, PI3Kδ and PI3Kγ with IC50s of 2, 3, 7, 14 and 16 nM, respectively. |
|
T10804 |
CHMFL-PI3KD-317
|
|
PI3K
,
PI4K
|
|
CHMFL-PI3KD-317 is a highly potent, selective and orally active PI3Kδ inhibitor, with an IC50 of 6 nM, and exhibits over 10-1500 fold selectivity over other class I, II and III PIKK family isoforms, such as PI3Kα (IC50, ... |
|
T6850L |
GSK2292767 FA
|
GSK2292767 FA(1254036-66-2 Free base) |
PI3K
|
|
GSK2292767 FA is a potent and selective inhibitor of PI3Kδ (pIC50 : 10.1).GSK2292767 FA is more than 500-fold more selective than other PI3K isoforms.GSK2292767 FA can be used in the study of respiratory diseases. |
